Related Experiment Video
Updated: Jun 26, 2026
High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
Published on: June 14, 2021
Evaluation of Multispecific Drugs Based on Patient-Derived Immunocompetent Tumor Organoids
Zihan Zhao1,2, Xiangyu Wu1, Tianyang Zhang2,3
1Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, 321 Zhongshan Rd, Nanjing, Jiangsu, 210008, China.
Abstract:
The evolution of antitumor drug development has transitioned from single-agent chemotherapy to targeted therapy, immunotherapy, and more recently, multispecific drugs. These innovative drugs target multiple cellular or molecular pathways simultaneously, offering a more comprehensive anticancer approach and addressing some of the limitations inherent in traditional monotherapies. However, preclinical assessment of multispecific drugs remains challenging, as conventional tumor models often lack the necessary complexity to accurately reflect the interactions between various cell types and targets. Patient-derived immunocompetent tumor organoids (PDITOs), which incorporate both tumor cells and immune cells, present a promising platform for the evaluation of these drugs. Beyond their use in drug evaluation, PDITOs can also be utilized in personalized drug screening and predicting patient-specific treatment outcomes, thus advancing both multispecific drug development and precision medicine. This perspective discusses the current landscape of multispecific drug development and the methodologies for constructing PDITOs. It also addresses the associated challenges and introduces the concept of employing these organoids to optimize the evaluation and rational design of multispecific drug therapies.
Insights
Multispecific drugs offer advanced cancer treatment, but preclinical models struggle to assess them. Patient-derived immunocompetent tumor organoids (PDITOs) provide a complex model for evaluating these novel antitumor therapies and advancing precision medicine.
Area of Science:
- Oncology
- Drug Development
- Translational Medicine
Background:
- Antitumor drug development has evolved from single-agent chemotherapy to complex multispecific drugs targeting multiple pathways.
- Traditional preclinical tumor models lack the complexity to accurately evaluate multispecific drugs due to limited cell and target interactions.
- Multispecific drugs offer a more comprehensive anticancer approach, addressing limitations of traditional monotherapies.
Purpose of the Study:
- To discuss the current landscape of multispecific drug development.
- To explore the potential of patient-derived immunocompetent tumor organoids (PDITOs) as a preclinical model for multispecific drugs.
- To highlight the role of PDITOs in personalized drug screening and predicting patient outcomes.
Main Methods:
- Review of current multispecific drug development strategies.
- Discussion of methodologies for constructing patient-derived immunocompetent tumor organoids (PDITOs).
- Analysis of challenges and opportunities in using PDITOs for drug evaluation.
Main Results:
- PDITOs, incorporating tumor and immune cells, offer a more complex and relevant preclinical model for multispecific drugs.
- These organoids can facilitate personalized drug screening and prediction of patient-specific treatment responses.
- PDITOs can aid in optimizing the evaluation and rational design of novel multispecific drug therapies.
Conclusions:
- Patient-derived immunocompetent tumor organoids (PDITOs) represent a promising platform for preclinical assessment of multispecific antitumor drugs.
- The use of PDITOs can significantly advance both the development of multispecific drugs and the field of precision medicine.
- Further development and application of PDITOs are crucial for optimizing cancer therapy strategies.
More Related Videos
12:41Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
05:33Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
Published on: September 6, 2024
